Table 2

Metabolic parameter values according to clinical characteristics and statistical associations between clinical and metabolic parameters

Clinical parameterMean MTV (95% CI)P valueMean TLG (95% CI)P valueMean SUVmax (95% CI)P valueMean SUVpeak (95% CI)P value
Age category
 <75 years69.0 (43.4–94.6)511 (259–764)15.0 (12.6–17.4)11.2 (9.3–13.1)
 ≥75 years69.0 (33.8–104)0.23437 (231–643)0.4315.0 (11.8–18.3)0.4710.2 (8.5–12.0)0.68
Gender
 Male77.3 (49.8–105)584 (309–859)14.5 (12.6–16.3)10.5 (8.9–12.0)
 Female47.7 (19.5–75.9)0.18269 (146–391)0.2116.4 (10.8–22.0)0.8612.3 (7.91–16.8)0.98
Histological type
 NSC71.2 (46.7–96.6)498 (264–733)14.6 (12.3–16.8)10.9 (9.1–12.6)
 SC55.0 (27.4–82.5)0.67479 (160–798)0.4817.3 (13.1–21.4)0.1211.8 (9.2–14.4)0.23
Prior chemotherapy
 Yes 55.3 (37.7–73.0) 437 (213–662)15.6 (13.3–18.0)11.4 (9.62–13.2)
 No 134 (49.9–218) 0.04 773 (312–1233)0.1712.0 (9.1–14.9)0.189.1 (6.84–11.3)0.28
Prior local treatment
 Yes 45.4 (27.6–63.2) 242.6 (162–323) 14.4 (10.6–18.2)10.3 (7.42–13.1)
 No 86.6 (52.4–121) 0.04 684 (344–1023) 0.02 15.4 (13.3–17.6)0.1511.6 (9.89–13.2)0.45
PDL1 expression
 <50%66.9 (17.5–116)479 (132–827)18.2 (10.8–25.6)13.3 (7.33–19.2)
 ≥50%91.9 (48.2–136)0.14706 (259–1153)0.3514.4 (11.9–16.9)0.5610.7 (8.84–12.7)0.87
  • Bold values have statistically significant differences.

  • MTV, whole-body metabolic tumor volume; NSC, non-squamous cell carcinoma; PDL1, programmed death receptor ligand 1; SC, squamous cell carcinoma; SUVmax, maximum standardized uptake value; SUVpeak, peak standardized uptake value; TLG, whole-body total lesion glycolysis.